Related Experiment Video
Updated: Jan 26, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the
Yan Li1, Lei Tao1, Zeping Zuo1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.
Abstract:
Lysine-specific demethylase1 (LSD1) plays a crucial role in cancer and has become a promising target for cancer therapy. However, the mechanism underlying the role of LSD1 in oncogenesis is poorly understood, and more effective LSD1 inhibitors are needed. Here we report the biological activity of a novel LSD1 inhibitor named ZY0511. ZY0511 specifically inhibited LSD1 activity and the proliferation of various human cancer cells especially the HeLa and HCT116 cells. ZY0511 significantly increased the expression of DDIT4, a known mTORC1 suppressor, which was a direct downstream target of LSD1 confirmed by ChIP-PCR. ZY0511-induced LSD1 inhibition upregulated the expression of DDIT4 by altering histone H3K4 methylation levels at its promoter, thus suppressing mTORC1 activity. Knockdown of DDIT4 attenuated the anticancer effect of ZY0511. Intraperitoneal administration of ZY0511 significantly prevented the growth of HCT116 and HeLa xenografts in mice and showed no detectable toxicity. Moreover, DDIT4 expression was correlated with the sensitivity of human cancer cells to chemotherapy. Taken together, ZY0511 showed therapeutic potential for solid tumors, the induction of DDIT4 may be used as a predictive biomarker of LSD1 inhibitors.
Insights
A novel drug, ZY0511, effectively inhibits lysine-specific demethylase 1 (LSD1) and cancer cell growth. It works by increasing DDIT4, a suppressor of mTORC1, showing therapeutic potential for solid tumors.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Lysine-specific demethylase 1 (LSD1) is implicated in cancer development but its mechanisms are not fully understood.
- There is a need for more effective LSD1 inhibitors for cancer therapy.
- Understanding LSD1's role in oncogenesis is crucial for targeted treatment strategies.
Purpose of the Study:
- To investigate the biological activity of a novel LSD1 inhibitor, ZY0511.
- To elucidate the mechanism of action of ZY0511 in cancer cells.
- To evaluate the therapeutic potential of ZY0511 in preclinical models.
Main Methods:
- Assessed LSD1 inhibition and cancer cell proliferation in vitro.
- Utilized ChIP-PCR to confirm DDIT4 as a direct downstream target of LSD1.
- Investigated the effect of ZY0511 on histone methylation and mTORC1 activity.
- Evaluated ZY0511 efficacy and toxicity in mouse xenograft models.
Main Results:
- ZY0511 specifically inhibited LSD1 activity and proliferation in various cancer cells, notably HeLa and HCT116.
- ZY0511 upregulated DDIT4 expression by altering histone H3K4 methylation at the DDIT4 promoter, suppressing mTORC1.
- Knockdown of DDIT4 diminished ZY0511's anti-cancer effects.
- ZY0511 treatment significantly inhibited tumor growth in xenograft models with no detectable toxicity.
- DDIT4 expression correlated with sensitivity to chemotherapy.
Conclusions:
- ZY0511 demonstrates significant therapeutic potential for solid tumors by inhibiting LSD1 and modulating the DDIT4/mTORC1 pathway.
- The induction of DDIT4 by ZY0511 offers a potential predictive biomarker for LSD1 inhibitor efficacy.
- Further research into ZY0511 and its downstream effects could lead to novel cancer treatments.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...

